
Arcutis Biotherapeutics, Inc.: updates and filings
Price
$27.15
November 19, 2026Market cap $3.4B
What Ploutos Investor adds for Arcutis Biotherapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Oct 28, 2026Officer or director change, Regulation FD disclosureForm8-K
- Oct 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operations, officer or director changeForm8-K
- Jul 16, 2026Officer or director change, Regulation FD disclosureForm8-K
- Jun 9, 2026Shareholder vote, other material eventsForm8-K
- May 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Financial statements and exhibitsForm8-K
- Apr 21, 2026Shares registered for employeesFormS-8
- Apr 21, 2026Annual report to shareholdersFormARS
- Apr 21, 2026Additional annual meeting materialFormDEFA14A
- Apr 21, 2026Annual meeting proxy statementFormDEF 14A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 25, 2026Shares registered for employeesFormS-8
- Feb 25, 2026Shelf registration for future offeringsFormS-3ASR
- Feb 25, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 25, 2026Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Oct 28, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Oct 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations, officer or director change | Document |
| Jul 16, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Jun 9, 2026 | 8-K | Shareholder vote, other material events | Document |
| May 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Financial statements and exhibits | Document |
| Apr 21, 2026 | S-8 | Shares registered for employees | Document |
| Apr 21, 2026 | ARS | Annual report to shareholders | Document |
| Apr 21, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 21, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 25, 2026 | S-8 | Shares registered for employees | Document |
| Feb 25, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Feb 25, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 25, 2026 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 9, 2019.
The full analysis
What do Arcutis Biotherapeutics's filings show?
The filings are where every one of Arcutis Biotherapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.